Bridging the gap: Postnatal research offers clues to tackling maternal obesity

Postnatal dietary patterns, physical activity status, and changes in body weight among obese women living in a highly deprived region in the UK.

FDA grants approval to Roche’s Tecentriq Hybreza for cancer

The FDA approval for Roche’s Tecentriq Hybreza was informed by data from the Phase IB/III IMscin001 trial. Credit: Marlon Trottmann/Shutterstock. The US Food and Drug

September 13, 2024

New trial shows promise of combination neoadjuvant immunotherapy for lung cancer

Patients with stage 1–3 non-small cell lung cancer (NSCLC) given a combination immunotherapy prior to surgery (neoadjuvant) had a better major pathological response (10% or

September 14, 2023

Aura’s bladder cancer data; Poseida discloses $15M milestone from Roche

Plus, news about Verastem Oncology, Bright Minds Biosciences and Telix Pharmaceuticals: Aura Biosciences unveils early bladder cancer data: The Boston biotech Sign up to read

October 19, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.